SCHEMBL4376465

SCHEMBL4376465

O=C(c1cc2cc(Cl)ccc2o1)N1CCN(C2CCCC2)CC1

nearest known ligand 0.71

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 4/20 0.71
NPC1 O15118 3/20 0.71
HRH4 Q9H3N8 1/20 0.68
SCN5A Q14524 1/20 0.58
SCN2A Q99250 1/20 0.58
SCN10A Q9Y5Y9 1/20 0.58
DPP4 P27487 1/20 0.57
DPP8 Q6V1X1 1/20 0.57
HRH3 Q9Y5N1 1/20 0.54
KDM4E B2RXH2 4/20 0.52
ALDH1A1 P00352 4/20 0.52
SMN1; SMN2 Q16637 3/20 0.52
L3MBTL1 Q9Y468 2/20 0.52
HSD17B10 Q99714 1/20 0.52
MAPT P10636 2/20 0.51
LMNA P02545 2/20 0.51
POLB P06746 1/20 0.49
PDE7B Q9NP56 1/20 0.48
TPSAB1 Q15661 1/20 0.48
TPSD1 Q9BZJ3 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL4380447 0.99 RAB9A (0.70) RAB9ANPC1HRH4SCN5ASCN2A
SCHEMBL30578692 0.83 RAB9A (0.74) RAB9ANPC1HRH4DPP4DPP8
SCHEMBL15949267 0.82 ALDH1A1 (0.61) RAB9ANPC1HRH4DPP4DPP8
SCHEMBL911720 0.82 ALDH1A1 (0.61) RAB9ANPC1HRH4DPP4DPP8
SCHEMBL30578705 0.80 RAB9A (0.69) RAB9ANPC1HRH4DPP4DPP8
SCHEMBL20274196 0.79 HRH4 (0.73) RAB9ANPC1HRH4DPP4DPP8
SCHEMBL8214661 0.78 RAB9A (0.67) RAB9ANPC1HRH4DPP4DPP8
SCHEMBL911034 0.78 HRH4 (0.57) RAB9ANPC1HRH4DPP4DPP8
SCHEMBL912042 0.78 HRH4 (0.57) RAB9ANPC1HRH4DPP4DPP8
SCHEMBL911079 0.78 MGLL (0.55) RAB9ANPC1HRH4DPP4DPP8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1421071-B1 SUBSTITUTED PIPERAZINE AND DIAZEPANE DERIVAIVES AS HISTAMINE H3 RECEPTOR MODULATORS HIGH POINT PHARMACEUTICALS LLC (US) 2009-11-18 EP claimed
EP-1421071-B1 SUBSTITUTED PIPERAZINE AND DIAZEPANE DERIVAIVES AS HISTAMINE H3 RECEPTOR MODULATORS HIGH POINT PHARMACEUTICALS LLC (US) 2009-11-18 EP disclosed
EP-1421071-B1 SUBSTITUTED PIPERAZINE AND DIAZEPANE DERIVAIVES AS HISTAMINE H3 RECEPTOR MODULATORS HIGH POINT PHARMACEUTICALS LLC (US) 2009-11-18 EP disclosed
US-20080113968-A1 Substituted piperazines and diazepanes NOVO NORDISK A/S (DK) 2008-05-15 US disclosed
US-20080113968-A1 Substituted piperazines and diazepanes NOVO NORDISK A/S (DK) 2008-05-15 US disclosed
US-7208497-B2 Substituted piperazines and diazepanes NOVO NORDISK A/S (DK) 2007-04-24 US disclosed
US-7208497-B2 Substituted piperazines and diazepanes NOVO NORDISK A/S (DK) 2007-04-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080113968-A1 Substituted piperazines and diazepanes HRH3, HRH4, HRH1 RAB9A 3209/4885NPC1 1743/4885HRH4 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.